Published DateClear

Start Date

End Date

Category

• Products2
• Business1
• Legal1

Organizations

• Bausch + Lomb73
• Eyes On Eyecare56
• Alcon, Inc.50
• American Optometric Association42
• Harrow34
• Glaukos30
• Topcon Healthcare26
• Regeneron25
• Coopervision22
• Aldeyra Therapeutics21

Tags

• AMD3
• Biosimilar3
• Injections3
• Products3
• Retinal Vein Occlusion (rvo)3
• Wet Amd3
• DME2
• Eylea2
• Diabetic Retinopathy2
• Retina2

• Organizations: Samsung Bioepis ✕

Clear all

Products

Harrow relaunches biosimilar Byooviz in the US

With commercial rights acquired from Samsung Bioepis, the FDA-approved interchangeable therapy to Lucentis is indicated for the treatment of wet AMD, RVO, and mCNV.

Legal

Samsung Bioepis and Regeneron settle EYLEA biosimilar US patent dispute

Settlement and license agreement clears the way for a January 2027 commercial launch of OPUVIZ 2 mg (aflibercept-yszy) injection.

Business

Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio

Acquisition includes two major anti-VEGF therapies for retinal diseases: OPUVIZ and BYOOVIZ, generic equivalents to EYLEA and Lucentis, respectively.

Products

FDA approves first interchangeable aflibercept biosimilars

Generic equivalents to Eylea demonstrate a comparable quality, safety, and efficacy profile for wet AMD, DME, RVO, and DR.